Cipepofol: A Breakthrough in Intravenous Anesthetics, Now FDA Approved
In a momentous development for the pharmaceutical industry, Cipepofol (CYPSEDO) Injection, a novel Class 1 intravenous anesthetic developed solely by Haisco Pharmaceutical Group, has successfully received marketing approval from the U.S. Food and Drug Administration (FDA). This approval signifies a historic milestone, as Cipepofol becomes the first innovative intravenous anesthetic created in China to penetrate the international market. By offering robust clinical evidence and addressing persistent challenges in anesthesia, Cipepofol represents a watershed moment that opens the gates to the global high-standard pharmaceutical arena.
Intravenous anesthetics play a crucial role in surgical procedures and intensive care, yet challenges such as injection pain and respiratory complications have persisted for years. Haisco's Cipepofol stands out as China's first independently developed intravenous anesthetic with global intellectual property rights. The drug has been authorized in China for various applications, including sedation for non-tracheal intubation surgeries, as well as induction and maintenance of general anesthesia.
The journey in developing Cipepofol began in 2012 when Haisco's research team faced numerous hurdles in refining its molecular structure. By utilizing cutting-edge techniques like introducing a chiral cyclopropyl group and conducting extensive safety evaluations, they successfully formulated a drug that enhances both efficacy and safety in IV anesthesia. As a result, various clinical studies conducted worldwide revealed that Cipepofol not only offers a rapid onset and quick recovery but also significantly lowers the incidence of serious respiratory issues and cardiovascular reactions.
Cipepofol's development has gained momentum, with its initial approval from the National Medical Products Administration (NMPA) in December 2020, alongside subsequent indications for its diverse applications in anesthesia and sedation. It gained further recognition in September 2025 after obtaining additional approvals for use in children and adolescents for the induction and maintenance of general anesthesia.
As of May 2026, Cipepofol has been integrated into over 20 clinical guidelines and consensus documents, embracing its significance in the field of anesthesia. It has accumulated usage across 3,300 medical institutions, making a profound impact by benefiting over 40 million patient visits in China alone. This remarkable uptake emphasizes the high clinical value and confidence built around Cipepofol.
Cipepofol's international journey embodies a transition from "Made in China" to "Innovated in China." Following its FDA approval for clinical trials in 2021, Cipepofol was exempted from Phase II trials in the United States, directly advancing to pivotal Phase III studies. By the conclusion of these studies in 2024, Cipepofol had demonstrated superior efficacy compared to conventional treatment methods. In July 2025, backed by further robust clinical evidence, Haisco submitted the New Drug Application (NDA) to the U.S. FDA, culminating in the recent marketing approval.
This achievement does not only validate Cipepofol’s clinical excellence but also underscores the capability of Chinese pharmaceutical firms to innovate and thrive beyond their borders. Haisco, propelled by this FDA endorsement, is now actively pursuing commercialization efforts in the United States while strategizing potential market entry into Europe. The firm aims to deliver innovative and high-quality patient solutions on a global scale, ultimately enhancing health outcomes for patients worldwide.
In a groundbreaking field that constantly evolves, Cipepofol is set to lead the way in the anesthetics market—signifying the potential of Chinese innovation to influence global healthcare. Haisco's commitment to research and development remains a cornerstone of its strategy, reflecting its ambition to cater to unmet medical needs and elevate patient care worldwide.
Intravenous anesthetics play a crucial role in surgical procedures and intensive care, yet challenges such as injection pain and respiratory complications have persisted for years. Haisco's Cipepofol stands out as China's first independently developed intravenous anesthetic with global intellectual property rights. The drug has been authorized in China for various applications, including sedation for non-tracheal intubation surgeries, as well as induction and maintenance of general anesthesia.
The journey in developing Cipepofol began in 2012 when Haisco's research team faced numerous hurdles in refining its molecular structure. By utilizing cutting-edge techniques like introducing a chiral cyclopropyl group and conducting extensive safety evaluations, they successfully formulated a drug that enhances both efficacy and safety in IV anesthesia. As a result, various clinical studies conducted worldwide revealed that Cipepofol not only offers a rapid onset and quick recovery but also significantly lowers the incidence of serious respiratory issues and cardiovascular reactions.
Cipepofol's development has gained momentum, with its initial approval from the National Medical Products Administration (NMPA) in December 2020, alongside subsequent indications for its diverse applications in anesthesia and sedation. It gained further recognition in September 2025 after obtaining additional approvals for use in children and adolescents for the induction and maintenance of general anesthesia.
As of May 2026, Cipepofol has been integrated into over 20 clinical guidelines and consensus documents, embracing its significance in the field of anesthesia. It has accumulated usage across 3,300 medical institutions, making a profound impact by benefiting over 40 million patient visits in China alone. This remarkable uptake emphasizes the high clinical value and confidence built around Cipepofol.
Cipepofol's international journey embodies a transition from "Made in China" to "Innovated in China." Following its FDA approval for clinical trials in 2021, Cipepofol was exempted from Phase II trials in the United States, directly advancing to pivotal Phase III studies. By the conclusion of these studies in 2024, Cipepofol had demonstrated superior efficacy compared to conventional treatment methods. In July 2025, backed by further robust clinical evidence, Haisco submitted the New Drug Application (NDA) to the U.S. FDA, culminating in the recent marketing approval.
This achievement does not only validate Cipepofol’s clinical excellence but also underscores the capability of Chinese pharmaceutical firms to innovate and thrive beyond their borders. Haisco, propelled by this FDA endorsement, is now actively pursuing commercialization efforts in the United States while strategizing potential market entry into Europe. The firm aims to deliver innovative and high-quality patient solutions on a global scale, ultimately enhancing health outcomes for patients worldwide.
In a groundbreaking field that constantly evolves, Cipepofol is set to lead the way in the anesthetics market—signifying the potential of Chinese innovation to influence global healthcare. Haisco's commitment to research and development remains a cornerstone of its strategy, reflecting its ambition to cater to unmet medical needs and elevate patient care worldwide.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.